HK1248114A1 - 通過人成肌細胞移植的疾病預防和緩解 - Google Patents
通過人成肌細胞移植的疾病預防和緩解Info
- Publication number
- HK1248114A1 HK1248114A1 HK18107641.8A HK18107641A HK1248114A1 HK 1248114 A1 HK1248114 A1 HK 1248114A1 HK 18107641 A HK18107641 A HK 18107641A HK 1248114 A1 HK1248114 A1 HK 1248114A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cure
- disease prevention
- myoblast transplantation
- human myoblast
- human
- Prior art date
Links
- 230000006806 disease prevention Effects 0.000 title 1
- 210000003098 myoblast Anatomy 0.000 title 1
- 238000002054 transplantation Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/968,982 US20150050300A1 (en) | 2013-08-16 | 2013-08-16 | Disease prevention and alleviation by human myoblast transplantation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1248114A1 true HK1248114A1 (zh) | 2018-10-12 |
Family
ID=49303813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18107641.8A HK1248114A1 (zh) | 2013-08-16 | 2018-06-13 | 通過人成肌細胞移植的疾病預防和緩解 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20150050300A1 (zh) |
EP (1) | EP2837683B1 (zh) |
JP (1) | JP2015051969A (zh) |
CN (3) | CN108042571A (zh) |
AU (1) | AU2013231029B2 (zh) |
ES (1) | ES2615553T3 (zh) |
HK (1) | HK1248114A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018055433A1 (en) | 2016-09-21 | 2018-03-29 | Peter Law | Autonomously controllable pull wire injection catheter, robotic system comprising said catheter and method for operating the same |
GB2567377A (en) * | 2016-10-27 | 2019-04-10 | Law Peter | Compositions comprising myoblasts for tumor growth inhibition and prevention of cancer cell metastasis by implantation |
AU2018375315A1 (en) * | 2017-11-28 | 2020-06-04 | The Board Of Trustees Of The University Of Illinois | Multi-chimeric cell and therapy for transplantation and treatment of immune deficiencies and genetic disorders |
CN113559125A (zh) * | 2020-04-26 | 2021-10-29 | 苏州大学 | 一种治疗糖尿病的干细胞药物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130141A (en) * | 1988-05-24 | 1992-07-14 | Law Peter K | Compositions for and methods of treating muscle degeneration and weakness |
US5139481A (en) * | 1991-08-07 | 1992-08-18 | The General Hospital Corporation | Treatment for type II diabetes |
CN1127343C (zh) | 1994-12-13 | 2003-11-12 | 彼得·K·罗 | 治疗哺乳动物疾病的成肌细胞组合物 |
CA2225185A1 (en) | 1997-08-11 | 1999-02-11 | Peter K. Law | Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities |
WO2002028470A1 (en) * | 2000-09-12 | 2002-04-11 | Law Peter K | Myogenic cell transfer catheter and method |
WO2003085092A2 (en) | 2002-04-01 | 2003-10-16 | Law Peter K | Cellular transplantation for heart regeneration |
CN1688701A (zh) * | 2002-08-09 | 2005-10-26 | 彼得·K·罗 | 成肌细胞转移治疗心力衰竭的机理 |
CA2496434A1 (en) * | 2002-08-23 | 2004-03-04 | Peter K. Law | Biologic skin repair and enhancement |
WO2004030706A2 (en) | 2002-10-01 | 2004-04-15 | Law Peter K | Bioactive implants |
WO2005020916A2 (en) | 2003-08-29 | 2005-03-10 | Law Peter K | Myoblast treatment of diseased or weakened organs |
-
2013
- 2013-08-16 US US13/968,982 patent/US20150050300A1/en not_active Abandoned
- 2013-09-17 AU AU2013231029A patent/AU2013231029B2/en active Active
- 2013-09-30 CN CN201711459144.3A patent/CN108042571A/zh active Pending
- 2013-09-30 CN CN201310455357.4A patent/CN103550784A/zh active Pending
- 2013-09-30 CN CN201710880691.2A patent/CN107648267A/zh active Pending
- 2013-10-04 EP EP13187352.3A patent/EP2837683B1/en active Active
- 2013-10-04 ES ES13187352.3T patent/ES2615553T3/es active Active
-
2014
- 2014-08-11 JP JP2014163691A patent/JP2015051969A/ja active Pending
-
2017
- 2017-08-30 US US15/690,803 patent/US10449219B2/en active Active
-
2018
- 2018-06-13 HK HK18107641.8A patent/HK1248114A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US10449219B2 (en) | 2019-10-22 |
CN103550784A (zh) | 2014-02-05 |
CN107648267A (zh) | 2018-02-02 |
JP2015051969A (ja) | 2015-03-19 |
AU2013231029A1 (en) | 2015-03-05 |
EP2837683A1 (en) | 2015-02-18 |
ES2615553T3 (es) | 2017-06-07 |
CN108042571A (zh) | 2018-05-18 |
AU2013231029B2 (en) | 2016-10-13 |
US20180000867A1 (en) | 2018-01-04 |
US20150050300A1 (en) | 2015-02-19 |
EP2837683B1 (en) | 2016-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286759A (en) | Therapeutic methods and preparations | |
GB201302447D0 (en) | Therapeutic and diagnostic target | |
HK1248114A1 (zh) | 通過人成肌細胞移植的疾病預防和緩解 | |
HK1219962A1 (zh) | 人抗白細胞介素- 抗體 | |
GB201313704D0 (en) | Engineered neural tissue | |
GB201303308D0 (en) | Therapeutic and diagnostic target | |
GB201319255D0 (en) | Therapeutic compositions and methods | |
GB201410990D0 (en) | General cure to diseases | |
GB201316908D0 (en) | Therapeutic and diagnostic target | |
GB201314515D0 (en) | Therapeutic and diagnostic target | |
GB201314502D0 (en) | Therapeutic and diagnostic target | |
GB201313865D0 (en) | Therapeutic and diagnostic target | |
GB201311899D0 (en) | Therapeutic and diagnostic target | |
GB201308759D0 (en) | Therapeutic and diagnostic target | |
GB201308013D0 (en) | Therapeutic and diagnostic target | |
GB201304740D0 (en) | Therapeutic and diagnostic target | |
GB201304402D0 (en) | Therapeutic and diagnostic target | |
GB201304406D0 (en) | Therapeutic and diagnostic target | |
GB201303648D0 (en) | Therapeutic and diagnostic target | |
GB201303573D0 (en) | Therapeutic and diagnostic target | |
GB201303529D0 (en) | Therapeutic and diagnostic target | |
GB201303532D0 (en) | Therapeutic and diagnostic target | |
GB201303571D0 (en) | Therapeutic and diagnostic target | |
GB201303535D0 (en) | Therapeutic and diagnostic target | |
GB201303486D0 (en) | Therapeutic and diagnostic target |